Mirati Therapeutics Announces Positive Results in Immuno-Oncology Combination Trials

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Apr 25, 2018 at 10:32 AM.

  1. #1 cafead, Apr 25, 2018 at 10:32 AM
    cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    32,990
    Likes Received:
    3
    via Mirati Therapeutics, Inc. (Nasdaq: MRTX) (the Company or Mirati), On 4/24/18 provided a progress update on its lead development programs and announced updated, positive clinical trial data for sitravatinib, a spectrum selective kinase inhibitor, and mocetinostat, a class I and IV HDAC inhibitor. The Company has been evaluating sitravatinib and mocetinostat in separate Phase 2 clinical trials in combination with checkpoint inhibitor therapy in non-small cell lung cancer (NSCLC) patients whose disease had progressed following prior treatment with a checkpoint inhibitor.

    article source
     
    Quote

Reply to Thread